February 23, 2018 / 1:11 PM / 6 months ago

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

Feb 23 (Reuters) - Ultragenyx Pharmaceutical Inc:

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

* ULTRAGENYX PHARMACEUTICAL - ‍FIRST COMMERCIAL LAUNCH OF CRYSVITA IS EXPECTED TO TAKE PLACE IN GERMANY IN Q2 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below